Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 74

Results For "CAS"

1856 News Found

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
News | November 28, 2023

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy


Surgeons at Aster RV Hospitals achieve milestone with removal of 345 gallstones
Healthcare | November 28, 2023

Surgeons at Aster RV Hospitals achieve milestone with removal of 345 gallstones

This surgery presented unique challenges, particularly due to the size of the gallbladder and the multitude of stones


DxVx plans to make a license-in agreement of OVM-200
News | November 25, 2023

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK


Lupin launches Vilfuro-G for COPD Management in India
News | November 23, 2023

Lupin launches Vilfuro-G for COPD Management in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide


AstraZeneca Pharma India receives permission to Import formulations of new drug for sale
News | November 23, 2023

AstraZeneca Pharma India receives permission to Import formulations of new drug for sale

The receipt of this permission paves way for the launch of Olaparib film coated tablets in India


Prevest Denpro launches range of innovative oral hygiene products ‘Oradox’
News | November 23, 2023

Prevest Denpro launches range of innovative oral hygiene products ‘Oradox’

The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care


Mandaviya visits Ayushman Bhav Health Pavilion at the 42nd IITF 2023
News | November 21, 2023

Mandaviya visits Ayushman Bhav Health Pavilion at the 42nd IITF 2023

Distributes Ayushman cards to several beneficiaries


Teva announces approval of a generic version of Forteo in US
Drug Approval | November 20, 2023

Teva announces approval of a generic version of Forteo in US

This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer